尼妥珠单抗联合调强放疗与单纯放疗治疗局部晚期鼻咽癌的效果比较

Effect comparison between Nimotuzumab combined with intensity-modulated radiotherapy and radiotherapy alone in the treatment of locally advanced nasopharyngeal carcinoma

目的比较尼妥珠单抗联合调强放疗(IMRT)与单纯放疗治疗局部晚期鼻咽癌的效果。方法选取2015年4月~2017年4月鞍山市肿瘤医院收治的100例局部晚期鼻咽癌患者作为研究对象,按照随机抽签法将其分为对照组(50例)和干预组(50例)。对照组患者单纯地进行IMRT,干预组患者在IMRT的治疗基础上应用尼妥珠单抗进行靶向治疗。比较两组患者的治疗效果、生存期[总生存期(OS)、无进展生存期(PFS)]、生活质量以及不良反应发生情况。结果干预组患者的治疗总有效率与疾病控制率均高于对照组,差异有统计学意义(P<0.05)。干预组患者的OS、PFS均长于对照组,生活质量评分高于对照组,差异有统计学意义(P<0.05)。干预组患者的不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论尼妥珠单抗联合IMRT治疗局部晚期鼻咽癌的效果明显优于单纯放疗,能提高局部控制率,提升患者生活质量,延长其生存期,值得推广应用。

Objective To compare the effect between Nimotuzumab combined with intensity-modulated radiotherapy(IMRT)and radiotherapy alone in the treatment of locally advanced nasopharyngeal carcinoma.Methods A total of 100 patients with locally advanced nasopharyngeal carcinoma who were admitted to Anshan Cancer Hospital from April 2015 to April 2017 were selected as the research subjects,and they were divided into the control group(50 cases)and the intervention group(50 cases)according to the random lottery method.Patients in the control group received IMRT alone,and patients in the intervention group were treated with Nimotuzumab for targeted therapy on the basis of IMRT.The therapeutic effect,survival period(overall survival[OS],progression-free survival[PFS]),quality of life,and incidence of adverse reactions were compared between the two groups.Results The total effective rate and disease control rate of the intervention group were higher than those of the control group,and the differences were statistically significant(P<0.05).The OS and PFS of the intervention group were longer than those of the control group,and the quality of life score was higher than that of the control group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the intervention group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion The effect of Nimotuzumab combined with IMRT is significantly better than that of radiotherapy alone in the treatment of locally advanced nasopharyngeal carcinoma.It can improve the local control rate,improve the quality of life of patients,and prolong their survival.It is worthy of popularization and application.